COMMUNIQUÉ DE PRESSE publié le 13/03/2024 à 08:05, il y a 2 années 4 mois BioNxt Reports Successful Results From ODF Cladribine PK Study BioNxt Solutions Inc. announces successful completion of comparative pharmacokinetic study for its oral dissolvable film Cladribine product for Multiple Sclerosis treatment, demonstrating rapid absorption similar to reference drug BioNxt Solutions Inc. Multiple Sclerosis Cladribine Pharmacokinetic Study Drug Delivery System
COMMUNIQUÉ DE PRESSE publié le 17/02/2024 à 01:50, il y a 2 années 5 mois BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
COMMUNIQUÉ DE PRESSE publié le 30/01/2024 à 05:48, il y a 2 années 6 mois BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
COMMUNIQUÉ DE PRESSE publié le 22/12/2023 à 09:05, il y a 2 années 7 mois BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
COMMUNIQUÉ DE PRESSE publié le 22/12/2023 à 01:50, il y a 2 années 7 mois BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
COMMUNIQUÉ DE PRESSE publié le 12/12/2023 à 09:05, il y a 2 années 7 mois BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
COMMUNIQUÉ DE PRESSE publié le 09/12/2023 à 04:30, il y a 2 années 7 mois BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
COMMUNIQUÉ DE PRESSE publié le 25/11/2023 à 01:44, il y a 2 années 8 mois Bionxt Solutions Announces Convertible Debenture and Interest Settlement
COMMUNIQUÉ DE PRESSE publié le 20/11/2023 à 09:05, il y a 2 années 8 mois BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
COMMUNIQUÉ DE PRESSE publié le 15/11/2023 à 15:10, il y a 2 années 8 mois BioNxt berichtet über das Entwicklungs- und Vermarktungsprogramm zu seinem neuen Produkt Cladribine ODF
Publié le 04/08/2026 à 18:32, il y a 2 heures 3 minutes Total number of voting rights and shares making up the share capital at July 31, 2026
Publié le 04/08/2026 à 17:45, il y a 2 heures 50 minutes INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 04/08/2026 à 17:00, il y a 3 heures 35 minutes Moderna annonce le début d'un essai clinique de phase 1 portant sur l’ARNm-1469, son vaccin expérimental contre l'ébolavirus de Bundibugyo
Publié le 04/08/2026 à 16:25, il y a 4 heures 10 minutes ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Publié le 04/08/2026 à 15:00, il y a 5 heures 35 minutes Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah
Publié le 04/08/2026 à 15:00, il y a 5 heures 35 minutes Secure Blockchain's Agentic Solutions Signs First Enterprise AI Customer
Publié le 04/08/2026 à 14:30, il y a 6 heures 5 minutes Agassi Sports Entertainment Launches Global "Let's Play" Pickleball and Padel Platform Initiative
Publié le 04/08/2026 à 20:05, il y a 30 minutes Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Publié le 04/08/2026 à 19:39, il y a 56 minutes EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again
Publié le 04/08/2026 à 18:25, il y a 2 heures 10 minutes Amendment to the Prospectus of the Company and the Key Information Documents of the SubFunds